Italia markets closed
FTSE MIB
34.492,41 +44,84 (+0,13%) Dow Jones
38.686,32 +574,84 (+1,51%) Nasdaq
16.735,02 -2,06 (-0,01%) Nikkei 225
38.487,90 +433,77 (+1,14%) Petrolio
77,18 -0,73 (-0,94%) Bitcoin EUR
62.346,85 +92,48 (+0,15%)
NVCR Jan 2025 30.000 call
OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
Alla chiusura: 11:27AM EDT
| Chiusura precedente | 3,5000 |
| Aperto | 3,4000 |
| Denaro | 2,7500 |
| Domanda | 3,5000 |
| Prezzo d'esercizio | 30,00 |
| Scadenza | 2025-01-17 |
| Min-Max giorno | 3,4000 - 3,4000 |
| Contratto - Min-Max | N/D |
| Volume | |
| Open Interest | 1,19k |
GlobeNewswireZai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in
© 2024 Yahoo. Tutti i diritti riservati.